205 related articles for article (PubMed ID: 18727058)
61. DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.
Ikeda M; Kurose A; Takatori E; Sugiyama T; Traganos F; Darzynkiewicz Z; Sawai T
Int J Oncol; 2010 May; 36(5):1081-8. PubMed ID: 20372780
[TBL] [Abstract][Full Text] [Related]
62. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy.
Taneja N; Davis M; Choy JS; Beckett MA; Singh R; Kron SJ; Weichselbaum RR
J Biol Chem; 2004 Jan; 279(3):2273-80. PubMed ID: 14561744
[TBL] [Abstract][Full Text] [Related]
63. Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells.
Schmidt F; Kunze M; Loock AC; Dobbelstein M
Oncotarget; 2015 Jan; 6(2):617-32. PubMed ID: 25593194
[TBL] [Abstract][Full Text] [Related]
64. Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.
DeNeve W; Valeriote F; Tapazoglou E; Everett C; Khatana A; Corbett T
Invest New Drugs; 1990 Feb; 8(1):17-24. PubMed ID: 2188927
[TBL] [Abstract][Full Text] [Related]
65. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression.
Wang Y; Huang JW; Li M; Cavenee WK; Mitchell PS; Zhou X; Tewari M; Furnari FB; Taniguchi T
Mol Cancer Res; 2011 Aug; 9(8):1100-11. PubMed ID: 21693595
[TBL] [Abstract][Full Text] [Related]
66. Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling.
Arnould S; Spanswick VJ; Macpherson JS; Hartley JA; Thurston DE; Jodrell DI; Guichard SM
Mol Cancer Ther; 2006 Jun; 5(6):1602-9. PubMed ID: 16818520
[TBL] [Abstract][Full Text] [Related]
67. Development of a high-content screening method for chemicals modulating DNA damage response.
Kim S; Jun DH; Kim HJ; Jeong KC; Lee CH
J Biomol Screen; 2011 Feb; 16(2):259-65. PubMed ID: 21233308
[TBL] [Abstract][Full Text] [Related]
68. Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R.
Gravells P; Hoh L; Canovas D; Rennie IG; Sisley K; Bryant HE
Br J Cancer; 2011 Mar; 104(7):1098-105. PubMed ID: 21386838
[TBL] [Abstract][Full Text] [Related]
69. Characterization of the role of a trimeric protein phosphatase complex in recovery from cisplatin-induced versus noncrosslinking DNA damage.
Vázquez-Martin C; Rouse J; Cohen PT
FEBS J; 2008 Aug; 275(16):4211-21. PubMed ID: 18647348
[TBL] [Abstract][Full Text] [Related]
70. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays.
Klokov D; MacPhail SM; Banáth JP; Byrne JP; Olive PL
Radiother Oncol; 2006 Aug; 80(2):223-9. PubMed ID: 16905207
[TBL] [Abstract][Full Text] [Related]
71. The effect of 5-fluorouracil on cisplatin induced DNA interstrand cross-linking in a mouse ascites tumor growing in vivo.
Lewin F; Ringborg U; Skog S; Tribukait B
Anticancer Drugs; 1995 Jun; 6(3):465-70. PubMed ID: 7670146
[TBL] [Abstract][Full Text] [Related]
72. Two-step procedure for evaluating experimentally induced DNA damage: Texas Red and Comet assays.
Ferris GJ; Shunkwiler LB; Kunos CA
Methods Mol Biol; 2015; 1249():183-91. PubMed ID: 25348306
[TBL] [Abstract][Full Text] [Related]
73. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
[TBL] [Abstract][Full Text] [Related]
74. Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay.
Spanswick VJ; Hartley JM; Hartley JA
Methods Mol Biol; 2010; 613():267-82. PubMed ID: 19997890
[TBL] [Abstract][Full Text] [Related]
75. In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.
Khongkow P; Middleton AW; Wong JP; Kandola NK; Kongsema M; de Moraes GN; Gomes AR; Lam EW
Methods Mol Biol; 2016; 1395():39-53. PubMed ID: 26910067
[TBL] [Abstract][Full Text] [Related]
76. Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks.
Turcotte V; Fortin S; Vevey F; Coulombe Y; Lacroix J; Côté MF; Masson JY; C-Gaudreault R
J Med Chem; 2012 Jul; 55(13):6194-208. PubMed ID: 22694057
[TBL] [Abstract][Full Text] [Related]
77. Comprehensive profiling of radiosensitive human cell lines with DNA damage response assays identifies the neutral comet assay as a potential surrogate for clonogenic survival.
Nahas SA; Davies R; Fike F; Nakamura K; Du L; Kayali R; Martin NT; Concannon P; Gatti RA
Radiat Res; 2012 Feb; 177(2):176-86. PubMed ID: 21962002
[TBL] [Abstract][Full Text] [Related]
78. Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients' Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome.
Sottile ML; Gómez LC; Redondo A; Ibarra J; García MB; Gonzalez L; Vargas-Roig LM; Nadin SB
J Histochem Cytochem; 2024 Mar; 72(3):173-188. PubMed ID: 38439738
[TBL] [Abstract][Full Text] [Related]
79. Can γH2AX be used to personalise cancer treatment?
Shah K; Cornelissen B; Kiltie AE; Vallis KA
Curr Mol Med; 2013 Dec; 13(10):1591-602. PubMed ID: 24206133
[TBL] [Abstract][Full Text] [Related]
80. γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies.
Shah K; Boghozian RA; Kartsonaki C; Shah KA; Vallis KA
Diagn Cytopathol; 2016 Feb; 44(2):141-6. PubMed ID: 26667983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
